New York, December 09, 2013 -- Moody's Investors Service said that St. Jude Medical's (STJ) announcement that its board of directors has authorized a $700 million share repurchase program, is credit negative but does not have an effect on its ratings (Baa1, Prime-2) at this time. For additional information, please see Moody's Issuer Comment on St. Jude Medical on www.moodys.com.
Vollständigen Artikel bei Moodys lesen